Clinical Trials Browser

NIH × Pancreatic Neoplasms × veliparib × Clear all

NCT02890355 2026-03-05

FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

123 enrolled 15 charts

Gastrointestinal

Pancreatic Neoplasms

NCT01585805 2025-03-11

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Active not recruiting

88 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00892736 2018-06-29

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Phase 1 Completed

98 enrolled

BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Hereditary Breast and Ovarian Cancer Syndrome, Triple Negative Breast Neoplasms

NCT01233505 2014-04-02

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Phase 1 Terminated

16 enrolled

BreastGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms

NCT01282333 2013-07-02

Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer

Phase 1 Terminated

44 enrolled

GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms